Lowest Price Guaranteed
Pages
190
Last Updated
June 2026
View Count
13953
The clinical trial design market is estimated to be worth $441 million in 2021 and is expected to grow at CAGR of 8% during the forecast period.
It is a well-known fact that development of a novel therapeutic intervention is both a time and cost intensive process. In fact, several reports have indicated that it can take around 10 years for a prescription medicine to transition from the discovery stage to the market, requiring investments worth over USD 2.5 billion. It is worth mentioning that clinical trials form an integral part of the overall drug development process, as they enable both innovators and regulators to assess the safety and efficacy of a drug candidate.The critical role of these studies can also be verified from the fact that they capture around 50% share of the total time and cost related investments made for the development of drug candidate. However, the conduct of trials is often fraught with several challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines.
Further, failure of a clinical trial can impose an enormous financial burden on sponsors, estimated to be in the range of USD 800 million (in case of therapies with niche / limited applications) to USD 1.4 billion (for a drug that is anticipated to be a blockbuster). It is further believed that a considerable portion of the losses can be avoided by efficient planning of trials. In other words, effective trial planning and design plays a pivotal role in enabling accurate, safe and timely execution of the study, across all sites.
Over the years, players engaged in the pharmaceutical industry have often leveraged novel and advanced technologies to address the existing challenges. In a similar manner, clinical trial sponsors are actively assessing available technologies / platforms with the intention of further optimizing the overall process. Recently, the clinical research segment has also witnessed a surge in number of vendors, offering a diverse range of services and solutions for clinical trial planning and design. Moreover, various startups and small firms have entered into collaborations in order to advance their innovations and offer specialized research expertise, services and tools. Additionally, several service providers engaged in this domain have shifted their focus on the development of software in order to automate the process and enable efficient planning and design of clinical trials. The aforementioned initiatives are focused on better facilitating / supporting the drug development process through early stage planning and design. Given the ongoing efforts to improve / expedite the clinical drug development process, we are led to believe that the clinical trial design market is likely to witness steady market growth during the forecast period.
 |
 |
 |
Examples of key companies engaged in clinical trial planning and design market (which have also been profiled in this market report; the complete list of companies is available in the full report) include PharmaLex, Emergo UL, Cytel, Health Policy Associate, CD BioSciences, LLX Solutions, SGS, ADM Korea, ClinAsia and BioPoint. This market report includes an easily searchable excel database of all the companies providing clinical trial design services, worldwide.
Several recent developments have taken place in the field of clinical trial design market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Clinical Trial Design Market, 2021-2030: Distribution by Phase of Trial (Phase I, Phase II, Phase III and Phase IV), Type of Service (Statistical Analysis Plan, eCRF, Site Identification and Selection, Medical Writing and Others), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the clinical trial design market. The market research report also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in clinical trial design market Amongst other elements, the market research report features:
The key objective of clinical trial design market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for clinical trial design market during the forecast period. We have also provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, over the forecast period 2021-2030. Additionally, the market report features the likely distribution of the current and forecasted opportunity across [A] phase of trial (phase I, phase II, phase III and phase IV), [B] type of service(s) offered (statistical analysis plan, eCRF, site identification and selection, medical writing and others), [C] therapeutic area (oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas) and [D] geography (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.
 |
 |
 |